JKJames David Katz

James David Katz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James David Katz has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Suraj Rajasimhan

    Clinical Pharmacy Specialist-Pharmacotherapy, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, USA

    3 shared publications
  • Adam Schiffenbauer

    Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, USA

    2 shared publications
  • Brian Walitt

    From the Human Cortical Physiology and Neurorehabilitation Section (W.H., E.R.B., F.I., D.D., R.F.S.-G., L.G.C.), Clinical Trials Unit (G.N.), Office of the Clinical Director, and Section of Infections of the Nervous System (E.B., B.W., A.N.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD

    2 shared publications
  • Brian Walitt

    National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.

    2 shared publications
  • Casey Allison Rimland

    Medical Scientist Training Program, University of North Carolina at Chapel Hill (UNC), Chapel Hill, NC, USA

    2 shared publications
  • Edward W. Cowen

    Dermatology Consultation Service, Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health 5 , Bethesda, MD

    2 shared publications

Latest Publications

  • Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC)

    by Elisa A Ferrante, Cornelia D Cudrici, Mahmood Rashidi, Yi-Ping Fu, Rebecca Huffstutler, Katherine Carney, Marcus Y Chen, Cynthia St Hilaire, Kevin Smith, Hadi Bagheri, et al.

    Background: Arterial calcification due to deficiency of CD73 (ACDC; OMIM 211800) is a rare genetic disease resulting in calcium deposits in arteries and small joints causing claudication, resting pain, severe joint pain, and deformities. Currently, there are no standard treatments for ACDC. Our previous work identified etidronate as a potential targeted ACDC treatment, using in vitro and in vivo disease models with patient-derived cells. In this study, we test the safety and effectiveness of etidronate in attenuating the progression of lower-extremity arterial calcification and vascular blood flow based on the computed tomography (CT) calcium score and ankle–brachial index (ABI). Methods: Seven adult patients with a confirmed genetic diagnosis of ACDC were enrolled in an open-label, nonrandomized, single-arm pilot study for etidronate treatment. They took etidronate daily for 14 days every 3 months and were examined at the NIH Clinical Center bi-annually for 3 years. They received a baseline evaluation as well as yearly follow up after treatment. Study visits included imaging studies, exercise tolerance tests with ABIs, clinical blood and urine testing, and full dental exams. Results: Etidronate treatment appeared to have slowed the progression of further vascular calcification in lower extremities as measured by CT but did not have an effect in reversing vascular and/or periarticular joint calcifications in our small ACDC cohort. Conclusions: Etidronate was found to be safe and well tolerated by our patients and, despite the small sample size, appeared to show an effect in slowing the progression of calcification in our ACDC patient cohort. (ClinicalTrials.gov Identifier NCT01585402)


  • Open Access

    A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome

    by David H. McDermott, Daniel Velez, Elena Cho, Edward W. Cowen, John J. DiGiovanna, Diana V. Pastrana, Christopher B. Buck, Katherine R. Calvo, Pamela J. Gardner, Sergio D. Rosenzweig, et al.

    BACKGROUND. Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome is a primary immunodeficiency disorder caused by heterozygous gain-of-function CXCR4 mutations. Myelokathexis is neutropenia from neutrophil retention in bone marrow and is associated with lymphopenia and monocytopenia. The CXCR4 antagonist plerixafor mobilizes leukocytes to the blood; however, safety and efficacy in WHIM syndrome are undefined. METHODS. In this investigator-initiated, single-center, randomized, quadruple-masked phase 3 crossover trial, we compared the total infection severity score (TISS) as primary endpoint in an intent-to-treat manner in 19 WHIM patients for 12-months on plerixafor versus 12-months on G-CSF, the standard-of-care for severe congenital neutropenia. RESULTS. Plerixafor was non-superior to G-CSF for TISS (p=0.65). In exploratory endpoints, plerixafor was non-inferior to G-CSF for maintaining neutrophil counts >500 cells/microliter (p=0.023) and was superior to G-CSF for maintaining lymphocyte counts >1000 cells/microliter (p<0.0001). Complete regression of a subset of large wart areas occurred on plerixafor in 5 of 7 patients with major wart burdens at baseline. Transient rash occurred on plerixafor, and bone pain was more common on G-CSF. There were no significant differences in drug preference or quality of life, or the incidence of drug failure or serious adverse events. CONCLUSIONS. Plerixafor was not superior in WHIM patients to G-CSF for TISS, the primary endpoint. Together with wart regression and hematologic improvement, the infection severity results support continued study of plerixafor as a potential treatment for WHIM syndrome.(Funded by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases; clinicaltrials.gov registration number, NCT02231879)


  • Open Access

    Person-Centered Care Starts with Community-Centered Medical Education: Medical Education Must Answer the Call for Diversity

    by James David Katz, Emily Rose, Katlin Poladian, Karina D. Torralba

    Civil unrest is a call for realignment of values in all aspects of society, including medical education. Systematic difference in the treatment of groups of individuals concerning educational curricula has previously been highlighted in South Africa during student-led campaigns to decolonialize and diversify medical curricula1. Institutional resistance that results in a failure to account for the politics of identity or for pluralistic thinking,1 implies that the academic ‘fence of unambiguous knowledge’ not only creates an ivory tower but it may simultaneously insulate itself from community input and access. Confronting the tension between communal meaning (which sanctions a culturally relevant curriculum) and privileged meaning (which derives from a monolithic mindset) demands that educators recognize that the scientific method is only one ‘way of knowing.’ In this manuscript we ask: Who possesses authoritative medical meaning-making? And, Who confers authoritativeness to academia?

  • Open Access

    Neutrophil-mediated carbamylation promotes articular damage in rheumatoid arthritis

    by Liam J. O’neil, Ana Barrera-Vargas, Donavon Sandoval-Heglund, Javier Merayo-Chalico, Eduardo Aguirre-Aguilar, Angel M. Aponte, Yanira Ruiz-Perdomo, Marjan Gucek, Hani El-Gabalawy, David A. Fox, et al.

    Carbamylated histone antibodies potentiate osteoclast formation and associate with bone erosion in rheumatoid arthritis.


  • Distribution and Functional Consequences of Somatic MAP2K1 Variants in Affected Skin Associated with Bone Lesions in Melorheostosis

    by Smita Jha, Aleksandra Ivovic, Heeseog Kang, Françoise Meylan, Eric P. Hanson, Casey Rimland, Eileen Lange, James Katz, Alison McBride, Andrew C. Warner, et al.


  • Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management

    by Sandra G. Williams, Arash Mollaeian, James D. Katz, Sarthak Gupta

    Immune checkpoint inhibitors (ICIs) have proved to be groundbreaking in the field of oncology and immunotherapy. However, immune system overactivation from ICIs has introduced a novel medical entit...


  • Open Access

    Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk

    by Suraj Rajasimhan, Omer Pamuk, James D. Katz

    The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway is a membrane-to-nucleus signaling cascade that effects activation of gene transcription. JAK inhibitors have demonstrated effectiveness in autoimmune diseases such as rheumatoid arthritis. An increased risk of infection, mainly varicella-zoster reactivation, with these new agents is of concern. Comorbid conditions, along with pharmacokinetic variations in drug metabolism in the older population, further increase the risk of adverse outcomes. Newly raised concerns for potential adverse effects such as deep vein thrombosis and pulmonary embolism are essential considerations for clinicians. Older patients are at increased risk because of multiple comorbid conditions and pharmacokinetic changes related to drug metabolism and excretion. Both the US FDA and the European Medicines Agency have issued warnings regarding this risk. These warnings highlight individuals aged > 50 years with concomitant cardiovascular risk factors. Furthermore, the FDA released a black box warning for increased thromboembolic risk associated with JAK inhibitors. As the use of these drugs increases, a solid understanding of adverse effects and risks is critical to those treating older adults.


  • Open Access

    Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-β/SMAD pathway

    by Heeseog Kang, Smita Jha, Aleksandra Ivovic, Nadja Fratzl-Zelman, Zuoming Deng, Apratim Mitra, Wayne A. Cabral, Eric P. Hanson, Eileen Lange, Edward W. Cowen, et al.

    Melorheostosis is a rare sclerosing dysostosis characterized by asymmetric exuberant bone formation. Recently, we reported that somatic mosaicism for MAP2K1-activating mutations causes radiographical “dripping candle wax” melorheostosis. We now report somatic SMAD3 mutations in bone lesions of four unrelated patients with endosteal pattern melorheostosis. In vitro, the SMAD3 mutations stimulated the TGF-β pathway in osteoblasts, enhanced nuclear translocation and target gene expression, and inhibited proliferation. Osteoblast differentiation and mineralization were stimulated by the SMAD3 mutation, consistent with higher mineralization in affected than in unaffected bone, but differing from MAP2K1 mutation–positive melorheostosis. Conversely, osteoblast differentiation and mineralization were inhibited when osteogenesis of affected osteoblasts was driven in the presence of BMP2. Transcriptome profiling displayed that TGF-β pathway activation and ossification-related processes were significantly influenced by the SMAD3 mutation. Co-expression clustering illuminated melorheostosis pathophysiology, including alterations in ECM organization, cell growth, and interferon signaling. These data reveal antagonism of TGF-β/SMAD3 activation by BMP signaling in SMAD3 mutation–positive endosteal melorheostosis, which may guide future therapies.